Dry Eye – Landscape & Forecast – Disease Landscape & Forecast (G7)

Dry eye disease (DED) is characterized by the loss of tear film homeostasis, caused by the inadequate production or the rapid evaporation of tears. The DED market is evolving rapidly, driven by innovative treatments and a growing understanding of the condition. Over the next ten years, this market is expected to be dynamic and highly competitive, especially in the United States. Therapies that promise clinical superiority, a faster onset of action, and more convenient administration than that of existing treatments are poised to launch. However, the approval of DED treatments in Europe and Japan remains limited, leading to the widespread use of off-label agents such as anti-inflammatories, artificial tears, and nonpharmacological approaches. Consequently, commercial opportunities exist in these regions for novel agents that can be successfully differentiated from current therapies.

Questions answered

• How large is the prescription drug-treatable DED population in the G7 countries?
• What is the current size of the DED market for key prescription therapies in the G7 countries? What pivotal events, including the launch of emerging therapies, will influence the market over the next decade?
• What is the current state of DED treatment? Which are the most important prescription drug classes / drugs in each market, and why? What are interviewed experts’ insights on current treatment options?
• What are the biggest areas of unmet need? Which late-phase therapies have the potential to fulfill these needs?

Geography

• United States, EU5, Japan.

Primary research

• Country-specific interviews with thought-leading ophthalmologists.
• Survey data collected for this and other Clarivate research.

Epidemiology

• Total prevalence of DED by country, including diagnosed and drug-treated patients.

Forecast

• 10-year, annualized, drug-level sales and patient share of key DED therapies through 2034, segmented by brands / generics and epidemiological subpopulations.

Drug treatments

• Coverage of key current and late-phase emerging therapies.

Product description

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
• Gauge the commercial outlook and impact of key market events.